Ingmar Hoerr

from Wikipedia, the free encyclopedia

Ingmar Hoerr (* 1968 ) is a German biologist . He is one of the founders of CureVac and has been CEO of Curevac again since March 2020.

Career

Hoerr did his doctorate in 1999 with Günther Jung in Tübingen on the subject of RNA vaccines for the induction of specific cytotoxic T lymphocytes (CTL) and antibodies . In this work he discovered that a stabilization of ribonucleic acid is possible. This discovery made it possible to easily use ribonucleic acid in the development of vaccines and immunotherapies .

In 2000, Hoerr and colleagues from the Tübingen working groups Günther Jung and Hans-Georg R Bäumenee founded the biopharmaceutical company CureVac . In 2018, he resigned his position as CEO and moved - as Chairman - to the Supervisory Board. On March 11, 2020, Hoerr took over the position of CEO again at CureVac, replacing his interim successor Daniel L. Menichella . A few days later, the company announced that Hoerr was absent for a certain period of time due to illness and could therefore not perform his role.

Individual evidence

  1. ↑ Ingmar Hoerr: RNA vaccine for the induction of specific cytotoxic T lymphocytes (CTL) and antibodies . Logos Berlin, February 15, 2000 , ISBN 3897223449 .
  2. ↑ Speaker - brand eins online. Accessed June 1, 2020 .
  3. ^ A medical revolution in the Tübingen technology park. Retrieved June 23, 2020 .
  4. ↑ Change at the top of CureVac | German. Accessed June 1, 2020 .
  5. ↑ curevac.com: Change in the board of CureVac: Company founder Ingmar Hoerr succeeds CEO Daniel Menichella. Press release from March 11, 2020
  6. ↑ curevac.com: CureVac with board news. Press release from March 16, 2020
personal data
SURNAME Hoerr, Ingmar
BRIEF DESCRIPTION German biologist
DATE OF BIRTH 1968